An Activatable Theranostic for Targeted Cancer Therapy and Imaging**
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bhuniya, Sankarprasad | - |
dc.contributor.author | Maiti, Sukhendu | - |
dc.contributor.author | Kim, Eun-Joong | - |
dc.contributor.author | Lee, Hyunseung | - |
dc.contributor.author | Sessler, Jonathan L. | - |
dc.contributor.author | Hong, Kwan Soo | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-05T09:26:52Z | - |
dc.date.available | 2021-09-05T09:26:52Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-04-22 | - |
dc.identifier.issn | 1433-7851 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98743 | - |
dc.description.abstract | A new theranostic strategy is described. It is based on the use of an all in one prodrug, namely the biotinylated piperazine-rhodol conjugate 4a. This conjugate, which incorporates the anticancer drug SN-38, undergoes self-immolative cleavage when exposed to biological thiols. This leads to the tumor-targeted release of the active SN-38 payload along with fluorophore 1a. This release is made selective as the result of the biotin functionality. Fluorophore 1a is 32-fold more fluorescent than prodrug 4a. It permits the delivery and release of the SN-38 payload to be monitored easily invitro and invivo, as inferred from cell studies and exvivo analyses of mice xenografts derived from HeLa cells, respectively. Prodrug 4a also displays anticancer activity in the HeLa cell murine xenograft tumor model. On the basis of these findings we suggest that the present strategy, which combines within a single agent the key functions of targeting, release, imaging, and treatment, may have a role to play in cancer diagnosis and therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-V C H VERLAG GMBH | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | METAL-ION | - |
dc.subject | RECEPTOR | - |
dc.subject | RELEASE | - |
dc.subject | TUMOR | - |
dc.title | An Activatable Theranostic for Targeted Cancer Therapy and Imaging** | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1002/anie.201311133 | - |
dc.identifier.scopusid | 2-s2.0-84899032171 | - |
dc.identifier.wosid | 000334396800037 | - |
dc.identifier.bibliographicCitation | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, v.53, no.17, pp.4469 - 4474 | - |
dc.relation.isPartOf | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | - |
dc.citation.title | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | - |
dc.citation.volume | 53 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 4469 | - |
dc.citation.endPage | 4474 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | METAL-ION | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordAuthor | biotin | - |
dc.subject.keywordAuthor | cellular imaging | - |
dc.subject.keywordAuthor | glutathione | - |
dc.subject.keywordAuthor | SN-38 | - |
dc.subject.keywordAuthor | theranostic | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.